At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 480 enrolled
Drug / intervention
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live +3 morebiological
Likely dose
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children
In Brief
A Phase 3 clinical trial evaluating Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Placebo, and 2 other interventions for Measles and 3 related conditions. Completed, enrolled 480 participants.
Detailed Summary
This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.
Study Details
Timeline
Phase 3CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 1998
Primary CompletionJan 1999
Study CompletionJun 1999
First PostedSep 2009
TodayJul 2026
First PostedSep 11, 2009
Enrollment StartMar 1, 1998
Primary CompletionJan 1, 1999
Study CompletionJun 1, 1999
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.8 years ago
Interventions
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Livebiological
a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
Comparator: Placebobiological
a single 0.5 mL subcutaneous placebo injection at Day 0
Comparator: Varivaxbiological
a single 0.5 mL subcutaneous injection of Varivax at Day 0
Comparator: M-M-R IIbiological
a single 0.5 mL subcutaneous injection of M-M-R II at Day 0